Efficacy of drug regimen with and without oseltamivir in hospitalized patients with COVID-19: A retrospective study.

Autor:	Shokri F; Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Rezapoor S; Department of Radiology, Imam Khomeini Hospital, Amol, Iran., Najafi M; Medical Technology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.; Radiology and Nuclear Medicine Department, Kermanshah University of Medical Sciences, Kermanshah, Iran., Asadi M; Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Alavije MK; Department of Infectious Disease, Imam Reza Hospital, Amol, Iran., Abolhassani M; Inv. Member, International Federation of Inventors' Associations-IFIA, Geneva, Switzerland., Moieneddin MH; Student Research Committee, Amol Faculty of Nursing, Mazandaran University of Medical Sciences, Sari, Iran., Ashrafi AM; Student Research Committee, Amol Faculty of Nursing, Mazandaran University of Medical Sciences, Sari, Iran., Gholipour N; Department of Critical Care Nursing, School of Nursing and Midwifery (Nasibeh), Mazandaran University of Medical Sciences, Sari, Iran., Naderi P; Department of Biology, Faculty of Cellular and Molecular Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran., Charati JY; Department of Biostatistics, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran., Alizadeh-Navaei R; Gastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran., Saeedi M; Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Science, Sari, Iran., Heidary M; Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran., Rostamnezhad M; Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Jazyk:	angličtina
Zdroj:	Vacunas [Vacunas] 2023 Apr-Jun; Vol. 24 (2), pp. 141-149. Date of Electronic Publication: 2022 Oct 04.
DOI:	10.1016/j.vacun.2022.09.077
Abstrakt:	Introduction: Coronavirus disease 2019 (COVID-19) is the most critical issue in nowadays medicine. We aimed to evaluate the use and therapeutic outcomes of oseltamivir, an antiviral drug for patients with COVID-19. Materials and Method: In an observational study conducted at Imam Khomeini Hospital in Amol, Iran, data for 544 patients with laboratory and CT scan result confirmed COVID-19 were retrospectively collected between February 24th and April 13th 2020. To compare the characteristics of patients based on gender, the chi-square test was used. Logistic regression was used to evaluate the effect of oseltamivir on the outcome of treatment. Logrank test were used to compare the length of hospital stay in people treated with oseltamivir and drugs other than oseltamivir. Results: Kaplan-Meier and logrank test showed no significant reduction in hospitalization time and survival rate following treatment with oseltamivir. However, a significant increase in lymphocytes count and reduction of C-reactive protein (CRP) level detected. Conclusion: Administration of oseltamivir for patients with COVID-19 didn't show any improvement in hospitalization duration and survival rate. Competing Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article. (© 2022 Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu